Last reviewed · How we verify

Domin (TALIPEXOLE)

FDA-approved active Small molecule Quality 17/100

Domin (generic name: TALIPEXOLE) is a drug. It is currently FDA-approved for Parkinson's disease.

TALIPEXOLE (Domin) is a marketed drug for Parkinson's disease, activating dopamine receptors to alleviate symptoms. Its key strength lies in its mechanism of action, which directly targets dopamine receptors, a critical pathway in managing Parkinson's disease. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic nameTALIPEXOLE
TargetD(3) dopamine receptor
ModalitySmall molecule
Therapeutic areaNeuroscience
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Domin

What is Domin?

Domin (TALIPEXOLE) is a Small molecule drug, indicated for Parkinson's disease.

What is Domin used for?

Domin is indicated for Parkinson's disease.

What is the generic name of Domin?

TALIPEXOLE is the generic (nonproprietary) name of Domin.

What development phase is Domin in?

Domin is FDA-approved (marketed).

What does Domin target?

Domin targets D(3) dopamine receptor.

Related